Genkyotex’s NOX1/4 inhibitor GKT831 has succeeded in a phase 2 trial in primary biliary cholangitis (PBC), a type of liver disease, by meeting both primary and secondary interim efficacy endpoints.
A clinical trial collaboration has been formed to assess Bristol-Myers Squibb's (BMS) Opdivo in combination with Infinity Pharmaceuticals' IPI-549 in patients with advanced urothelial cancer.
Verona Pharma has completed patient enrollment for a phase 2 trial for its nebulized RPL554 as an add-on to dual therapy using long-acting anti-muscarinic / long-acting beta2-agonists (LAMA/LABA) and triple therapy (LAMA/LABA with an inhaled corticosteroid) in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD).
ViiV Healthcare has reported positive results for its phase 3 BRIGHTE study of investigational fostemsavir at 48 weeks in heavily treatment-experienced (HTE) patients with HIV-1 infection.
Pfizer has signed a non-exclusive clinical development agreement with Novartis to study one or more combination therapies for the treatment of non-alcoholic steatohepatitis (NASH).
Swiss drugmaker Novartis released additional phase III results of brolucizumab from year two, which reaffirm superiority of the drug over aflibercept in reducing retinal fluid in patients with neovascular age-related macular degeneration (nAMD).
Esperion’s cholesterol drug bempedoic acid has succeeded in a phase 3 trial by achieving its efficacy endpoints and other key measures in patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH).
Bristol-Myers Squibb (BMS) has dosed the first subject in a clinical trial assessing the safety, pharmacokinetics and pharmacodynamics of BMS-986179, an investigational anti-CD-73 antibody, using Halozyme Therapeutics' Enhanze drug delivery technology.
Daiichi Sankyo has entered into a clinical trial collaboration agreement with Merck and Pfizer to evaluate the combination of its [fam-] trastuzumab deruxtecan (DS-8201) with avelumab and/or an investigational damage response (DDR) inhibitor of Merck, in patients with HER2 expressing or mutated solid tumors.
Merck’s anti-PD-1 therapy Keytruda has improved overall survival (OS) compared to standard of care as first line treatment for patients with recurrent or metastatic head and neck cancer (HNSCC) in the pivotal phase 3 Ketnote-048 trial.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.